

PRODUCT INFORMATION



Tasosartan

Item No. 29495

CAS Registry No.: 145733-36-4

Formal Name: 5,8-dihydro-2,4-dimethyl-8-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-pyrido[2,3-d]pyrimidin-7(6H)-one

Synonym: WAY-ANA-756

MF: C₂₃H₂₁N₇O

FW: 411.5


Purity: ≥98%

UV/Vis.: λ_{max}: 251 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tasosartan is supplied as a crystalline solid. A stock solution may be made by dissolving the tasosartan in the solvent of choice, which should be purged with an inert gas. Tasosartan is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of tasosartan in these solvents is approximately 2, 14, and 20 mg/ml, respectively.

Tasosartan is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, tasosartan should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Tasosartan has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tasosartan is an angiotensin II type 2 (AT₂) receptor antagonist (IC₅₀ = 1.2 nM in rat adrenal gland membranes).¹ It also binds to the AT₁ receptor (K_i = 46.6 nM in rat liver epithelial cells).² Tasosartan (3 mg/kg, intraduodenally) reduces the AT₂-induced pressor response in rats.³ It also decreases mean arterial pressure in a rat model of hypertension induced by renal artery constriction when administered intragastrically or intravenously at doses of 1 and 3 mg/kg.¹

References

1. Ellingboe, J.W., Collini, M.D., Quagliato, D., et al. Metabolites of the angiotensin II antagonist tasosartan: The importance of a second acidic group. *J. Med. Chem.* **41**(22), 4251-4260 (1998).
2. Hines, J., Fluharty, S.J., and Sakai, R.R. The angiotensin AT₁ receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling. *Eur. J. Pharmacol.* **384**(1), 81-89 (1999).
3. Ellingboe, J.W., Antane, M., Nguyen, T.T., et al. Pyrido[2,3-d]pyrimidine angiotensin II antagonists. *J. Med. Chem.* **37**(4), 542-550 (1994).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/30/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM